Central neurotoxicity of immunomodulatory drugs in multiple myeloma

Main Article Content

Urmeel H. Patel
Muhammad A. Mir
Jeffrey K. Sivik
Divisha Raheja
Manoj K. Pandey
Giampaolo Talamo *
(*) Corresponding Author:
Giampaolo Talamo | gtalamo@hmc.psu.edu


Immunomodulatory drugs (IMiDs) currently used in the treatment of multiple myeloma, are thalidomide, lenalidomide and pomalidomide. One of the most common side effects of thalidomide is neurotoxicity, predominantly in the form of peripheral neuropathy. We report 6 cases of significant central neurotoxicity associated with IMiD therapy. Treatment with thalidomide (1 patient), lenalidomide (4 patients), and pomalidomide (1 patient) was associated with various clinical manifestations of central neurotoxicity, including reversible coma, amnesia, expressive aphasia, and dysarthria. Central neurotoxicity should be recognized as an important side effect of IMiD therapy.

Downloads month by month


Download data is not yet available.

Article Details

Most read articles by the same author(s)